Use of hematopoietic growth factors in the treatment of acute myelogenous leukemia

Current Opinion in Hematology

Volumn 4, Issue 3, 1997, Pages 191-195

  Ganser, Arnold ^a   Heil, Gerhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LEUKEMIA REMISSION; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0030859364     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199704030-00006     Document Type: Review

References (27)

1. Hoelzer D, Seipelt G: Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the treatment of myeloid leukemia. Curr Opin Hematol 1995, 2:196-203.
2. Geller RB: Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996, 14:1371-1382.
3. Schiffer CA: Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996, 88:3675-3685. An outstanding review that provides an excellent overview of recently published randomized trials dealing with hematopoietic growth factors in AML therapy. The author concludes that GM-CSF or G-CSF given after induction and possibly consolidation therapy can reduce the duration of chemotherapy-induced neutropenia without a consistent effect on infectious complications or on prognosis. In contrast, the application of a growth factor, mainly GM-CSF, concomitantly with chemotherapy to enhance the antileukemic effect (priming concept) appears to have no role in AML therapy.
4. Löwenberg B, Touw IP: Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993, 81:2811-2892.
5. Ohno R, Tomonaga M, Kobayashi T, Kamamura A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, et al.: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990, 323:871-877.
6. Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB, et al.: Treatment of poor prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1990, 75:1766-1769.
7. Bettelheim P, Valent P, Andreeff M, Tafuri A, Haimi J, Gorischek C, Muhm M, Sillaber C, Haas O, Vieder L, et al.: Recombinant human granulocyte-macrophage colony-stimulating factor in combination with Standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991, 77:700-711.
8. Büchner T, Hiddemann W, Königsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, Freire EA, Innig G, Maschmeyer G, Ludwig WD: Recombinant human granulocyte macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991, 78:1190-1197.
9. 2, yeast) conferred significant benefits in terms of neutrophil recovery (≤ 500/μL: 13 versus 17 days), treatment related toxicity and grade 4/5 infectious complications. The CR rate was higher under GM-CSF (60% versus 44%) with a significant prolongation of the median survival under GM-CSF (10.6 versus 4.8 months) due to a reduction in early mortality. However, the patient number was relatively small and the follow-up was short.
10. Heil G, Chadid L, Hoelzer D, Seipelt G, Mitrou P, Huber C, Kolbe K, Mertelsmann R, Lindemann A, Frisch J, et al.: GM-CSF in a double-blind randomized placebo-controlled trial in therapy of adult patients with de novo acute myeloid leukemia. Leukemia 1995, 9:3-9.
11. Stone R, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer C: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 1995, 332:1671-1677. Double-blind randomized, placebo-controlled trial with GM-CSF (5 μg/kg, E. coli) given after induction chemotherapy for 388 elderly (age ≥ 60 years, median = 69 years) AML patients. Although GM-CSF significantly reduced the duration of neutropenia (15 versus 17 days) it had no significant impact on the incidence of severe infections, treatment-related mortality, or CR rate thus questioning the role of GM-CSF in this situation.
12. Witz F, Harrousseau JL, Sadoun A, Guyotat D, Berthou C, Cahn JY, Gardin C, Lioure B, Witz B, Desablens B, et al.: GM-CSF during and after remission induction treatment for elderly patients with acute myeloid leukemia (AML) [abstract]. Blood 1995, 86 (suppl 1):512.
13. Löwenberg B, Boogaerts MA, Vellenga E, Ossenkoppele G, Dekker AW, van der Lelie J, Schouten HC, Fopp M, Gratwohl A, Fev M, et al.: Various modalities of use of GM-CSF in the treatment of acute myelogenous leukemia (AML): a HOVON-SAKK randomized study (HOVON-4A) [abstract]. Blood 1995, 86 (suppl 1):512.
14. Löwenberg B, Suciu S, Zittoun R, Ossenkoppele G, Boogaerts MA, Wijermans P, Vellenga E, Berneman Z, Dekker AW, Sonneveld P, et al.: GM-CSF during as well as after induction chemotherapy (CT) in elderly patients with acute myeloid leukemia (AML): the EORTC-HOVON phase III trial (AML 11). Blood 1995, 86 (suppl 1):433a.
15. Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996, 14:2150-2159. A randomized trial to assess the value of GM-CSF for AML induction therapy. A total of 102 patients were randomly selected to receive GM-CSF (5 μg/kg, E. coli) either concomitantly with chemotherapy (+/-), thereafter (-/+), concomitantly and therafter chemotherapy (+/+) or no GM-CSF (-/-). Priming with GM-CSF had no effect on the CR rate (72% versus 77%), whereas GM-CSF given after chemotherapy significantly decreased the CR rate in comparison with the control group (48% in the -/+ arm, 46% in the +/+ arm, versus 77% in the -/-arm). It has to be taken into consideration, however, that the remission status was assessed under GM-CSF. As a consequence, an underestimation of the CR rate due to a stimulation of early normal progenitors that could simulate the persistence or reoccurence of leukemic blasts cannot be excluded. Further randomized trials including larger series of patients are needed to settle this issue.
16. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R, Mandelli F, Ferrant A, Auzenneau G, Tilly H, et al.: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 1995, 332:1678-1683. A randomized trial with G-CSF (lenograstim, 5 μg/kg) or placebo given from day 9 after induction chemotherapy for elderly AML patients (n = 173, median age = 71 years). G-CSF significantly reduced the duration of neutropenia (21 versus 27 days) without a significant effect on the incidence of severe infections or on induction mortality rate. The CR rate was significantly higher in the G-CSF group (70% versus 47%) due to a reduced incidence of resistant leukemia. This effect did, however, not translate into a significant difference in overall survival.
17. Heil G, Hoelzer D, Sanz MA, Lechner K, Yin JL, Papa G, Noens L, Ho J, O'Brien C, Matcham J, et al.: Results of a randomized, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia [abstract]. Blood 1995, 86 (suppl 1):267.
18. Godwin JE, Kopecky KJ, Head DR, Hynes HE, Balcerzak SP, Appelbaum FR: A double-blind placebo-controlled trial of G-CSF in elderly patients with previously untreated acute myeloid leukemia [abstract]. Blood 1995, 86 (suppl 1):434.
19. Ohno R, Naoe T, Kanamura A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, et al. for the Leukemia Study Group: A double-blind controlled study of granulocyte-colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994, 83:2086-2092.
20. Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al.: Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994, 12:671-678.
21. Wielenga JJ, Vellenga E, Groenewegen A, Sonneveld P, Löwenberg B: Recombinant human interleukin-3 (rH IL-3) in combination with remission induction chemotherapy in patients with relapsed acute myelogenous leukemia (AML): a phase I/II study. Leukemia 1996, 10:43-47.
22. Giralt S, Escudier S, Kantarjian H, Deisseroth A, Freireich EJ, Andersson BS, O'Brien S, Andreeff M, Fisher H, Cork A, et al.: Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993, 329:757-761.
23. Dombret H, Daniel MT, Chaibi P, Rousselot P, Jonveaux P, Chomienne C, Degos L: In vivo administration of granulocyte colony-stimulating factor (G-CSF) enhances the granulocytic maturation of leukemic cells in patients with acute myeloid leukemia (AML) and the t(8;21) translocation. Blood 1995, 86 (suppl 1):691a.
24. Sugawara T, Sato A, Shishido T, Okuda M, Kameoka J, Meguro K, Endo K, Yoshinaga K: Case reports: complete remission in acute myeloid leukaemia after treatment with recombinant human granulocyte colony-stimulating factor and high dose intravenous methylprednisolone. Br J Haematol 1991, 77:561-562.
25. Bassan R, Rambaldi A, Amaru R, Motta T, Barbui T: Unexplained remission of acute myeloid leukaemia after GM-CSF. Br J Haematol 1994, 87:835-838.
26. Archimbaud E, Ottmann O, Yin JAL, Lechner K, Dombret H, Sanz MA, Herrmann F, Gruss H, Fenaux P, Ganser A, et al.: A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de novo acute myeloid leukaemia (AML): early results [abstract]. Blood 1996, 88 (suppl 1):447.
27. Luo R, Erder H, Heil G, Ganser A, Lechner K, Yin JL, Szer J, Barge A: Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukaemia (AML) [abstract]. Blood 1996, 88 (suppl 1):209.